MarketCapExport financials
Mesoblast Limited (MESO)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Mesoblast Limited Income Statement 2025-2011 | MESO
Brief overview of income trends at Mesoblast Limited
The figures are compared over a five-year interval. Mesoblast Limited reported revenue of 32.2 million dollars in 2020 and 17.2 million dollars by 2025. The total change was −46.5%, with a CAGR of approximately −11.8%. Revenue ended the period on a sustained downward trend.
The operating result measured by EBITDA moved from $0 to $0, or . EBITDA margin moved from 0% to 0%. Operating efficiency did not change materially.
The final result was −$77.9 million initially and −$102 million in the final year. Larger losses indicate rising pressure on the business.
What the figures show
The financial trajectory is weak and requires a cautious interpretation. The positive side is supported by consistent operating efficiency. The weaker side of the profile includes weak sales momentum, declining net profitability and a narrow EBITDA buffer. Further direction will depend on top-line growth, operating profitability, and net income.
Annual Income Statement Mesoblast Limited
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
12.5 B | - | - | 2.04 B | 2.42 B | 4.23 B | 513 M | 659 M | 564 M | 299 M | 939 M | 1.28 B | 1.56 B | 1.81 B | 2.17 B |
Shares |
1.21 B | 987 M | 778 M | 683 M | 605 M | 529 M | 98.9 M | 93.1 M | 79.9 M | 72.9 M | 64.8 M | 64.5 M | 59.1 M | 57.1 M | 43.8 M |
Historical Prices |
10.4 | - | - | 2.99 | 4.8 | 8.49 | 7.37 | 4.12 | 5.84 | 5.35 | 6.36 | 17.8 | 26.4 | 27.5 | 35.2 |
Net Income |
-102 M | -88 M | -81.9 M | -91.3 M | -98.8 M | -77.9 M | -89.8 M | -35.3 M | -76.8 M | -4.13 M | -119 M | -81 M | -61.7 M | -71.1 M | 90.6 M |
Revenue |
17.2 M | 5.9 M | 7.5 M | 10.2 M | 7.46 M | 32.2 M | 16.7 M | 17.3 M | 2.41 M | 42.5 M | 23.7 M | 26 M | 28.8 M | 38.3 M | 121 M |
Cost of Revenue |
5.13 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
12.1 M | - | - | - | - | - | - | 11.8 M | - | - | - | - | - | - | - |
Interest Expense |
21.8 M | 20.7 M | 19.4 M | 16.9 M | 15.9 M | 14.7 M | 11.7 M | 1.83 M | - | - | - | - | - | - | - |
EBITDA |
- | - | - | - | - | - | -78.1 M | -72.2 M | -87 M | -53.7 M | -111 M | -71.3 M | -59.3 M | -26.3 M | 93.9 M |
Operating Expenses |
12.1 M | - | - | - | - | - | - | 86.7 M | - | - | - | - | - | - | - |
General and Administrative Expenses |
39.3 M | 25 M | 27.5 M | - | - | - | 21.6 M | 21.9 M | 23 M | 22.5 M | 36.2 M | 26.6 M | 30.7 M | 28.1 M | 11.8 M |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Mesoblast Limited
| 2025-Q4 | 2025-Q2 | 2024-Q4 | 2024-Q2 | 2023-Q4 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
1.29 B | 1.21 B | 1.14 B | 987 M | 875 M | 778 M | 737 M | 737 M | 696 M | - | 650 M | 648 M | 648 M | - | 604 M | 586 M | 582 M | - | 538 M | 534 M | 499 M | 492 M | 499 M | 492 M | 479 M | - | 473 M | 471 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-40.2 M | -102 M | -47.9 M | -88 M | -32.5 M | -81.9 M | -18.6 M | -24.5 M | -16.9 M | - | -21.3 M | -25.9 M | -22.6 M | - | -26.5 M | -25.7 M | -24.5 M | - | -15.3 M | -24.6 M | -5.48 M | -24.6 M | -25 M | -24.6 M | -19.5 M | - | -21.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
51.3 M | 17.2 M | 3.16 M | 5.9 M | 3.39 M | 7.5 M | 1.94 M | 2.13 M | 1.5 M | - | 2.01 M | 2.38 M | 3.59 M | - | 1.92 M | 2.24 M | 1.3 M | - | 12.2 M | 2.21 M | 17 M | 1.87 M | 1.25 M | 1.87 M | 11.6 M | - | 1.07 M | 13.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
7.6 M | 5.13 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
43.7 M | 12.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
11.3 M | 21.8 M | 10.7 M | 20.7 M | 10.2 M | 19.4 M | 4.9 M | 4.9 M | 4.55 M | - | 4.3 M | 4.06 M | 4.14 M | - | 3.95 M | 3.99 M | 3.93 M | - | 3.73 M | 3.6 M | 3.58 M | 2.49 M | 3.14 M | 2.49 M | 2.65 M | - | 423 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
43.7 M | 12.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
28.5 M | 39.3 M | 18 M | 25 M | - | 27.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Mesoblast Limited (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Biotechnology industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Edesa Biotech
EDSA
|
$ 2.01 | -19.28 % | $ 11.4 M |  USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$ 15.12 | -0.72 % | $ 978 M | USA |
 |
Achieve Life Sciences
ACHV
|
$ 6.78 | 0.89 % | $ 296 M | USA |
 |
Fulcrum Therapeutics
FULC
|
$ 3.72 | -0.13 % | $ 236 M | USA |
 |
Immutep Limited
IMMP
|
$ 3.53 | -7.11 % | $ 5.14 B |  Australia |
 |
Iovance Biotherapeutics
IOVA
|
$ 8.09 | -1.04 % | $ 2.89 M | USA |
 |
Evogene Ltd.
EVGN
|
$ 0.37 | 28.7 % | $ 2.91 M |  Israel |
 |
Armata Pharmaceuticals
ARMP
|
$ 3.71 | -2.5 % | $ 134 M | USA |
 |
Axsome Therapeutics
AXSM
|
$ 141.12 | 5.34 % | $ 7.02 B | USA |
 |
Keros Therapeutics
KROS
|
$ 9.32 | 1.64 % | $ 347 M | USA |
 |
Champions Oncology
CSBR
|
$ 4.85 | 0.21 % | $ 67.1 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
$ 10.6 | -2.12 % | $ 303 M | USA |
|
Forte Biosciences
FBRX
|
$ 76.99 | 0.03 % | $ 997 M | USA |
 |
Immunic
IMUX
|
$ 8.06 | 1.26 % | $ 1.25 B | USA |
 |
DiaMedica Therapeutics
DMAC
|
$ 9.7 | 0.47 % | $ 456 M | USA |
 |
Grifols, S.A.
GRFS
|
$ 8.74 | 0.63 % | $ 5.94 B |  Spain |
 |
Incyte Corporation
INCY
|
$ 120.28 | -1.32 % | $ 23.5 B | USA |
 |
AC Immune SA
ACIU
|
$ 2.32 | -4.92 % | $ 234 M |  Schweiz |
 |
Aldeyra Therapeutics
ALDX
|
$ 0.64 | 0.53 % | $ 38.4 M | USA |
 |
Aptose Biosciences
APTO
|
- | -45.71 % | $ 1.2 M |  Canada |
 |
Precision BioSciences
DTIL
|
$ 9.47 | -2.17 % | $ 121 M | USA |
 |
AIM ImmunoTech
AIM
|
$ 0.14 | -11.15 % | $ 227 K | USA |
 |
Ascendis Pharma A/S
ASND
|
$ 256.21 | -1.4 % | $ 15.5 B |  Danmark |
 |
ANI Pharmaceuticals
ANIP
|
$ 71.31 | 5.19 % | $ 1.43 B | USA |
 |
Actinium Pharmaceuticals
ATNM
|
$ 1.56 | 1.3 % | $ 48.7 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
$ 1.31 | -0.76 % | $ 349 M |  Britain |
|
Monopar Therapeutics
MNPR
|
$ 71.42 | -3.16 % | $ 529 M | USA |
 |
BridgeBio Pharma
BBIO
|
$ 78.67 | 0.95 % | $ 15.1 B | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
$ 7.53 | -1.38 % | $ 1.58 B | USA |
 |
Bicycle Therapeutics plc
BCYC
|
$ 3.68 | -2.39 % | $ 255 M | Britain |
 |
Coherus BioSciences
CHRS
|
$ 0.64 | -21.66 % | $ 75 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
$ 27.45 | 4.77 % | $ 3.49 B | USA |
 |
Cellectis S.A.
CLLS
|
$ 1.12 | -0.45 % | $ 112 M |  France |
 |
BeyondSpring
BYSI
|
$ 0.6 | -2.21 % | $ 24.7 M | USA |
 |
Alkermes plc
ALKS
|
$ 46.48 | 0.67 % | $ 7.66 B |  Irlanda |
 |
Altimmune
ALT
|
$ 1.94 | -8.51 % | $ 171 M | USA |
 |
Cardiff Oncology
CRDF
|
$ 0.79 | -0.77 % | $ 52.8 M | USA |
 |
Citius Pharmaceuticals
CTXR
|
$ 0.5 | -5.43 % | $ 5.53 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
$ 9.41 | -0.84 % | $ 258 M | Israel |
 |
Arrowhead Pharmaceuticals
ARWR
|
$ 49.04 | -0.41 % | $ 6.56 B | USA |
 |
Atara Biotherapeutics
ATRA
|
$ 8.18 | -0.73 % | $ 103 M | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
$ 16.3 | -1.93 % | $ 2.19 B | Canada |
 |
Cullinan Management
CGEM
|
$ 11.34 | -3.32 % | $ 683 M | USA |
 |
BioNTech SE
BNTX
|
$ 87.2 | -0.36 % | $ 21.1 B |  Germany |
 |
Collegium Pharmaceutical
COLL
|
$ 24.47 | -0.97 % | $ 775 M | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
$ 3.95 | 12.07 % | $ 52.6 M | USA |
|
Enlivex Therapeutics Ltd.
ENLV
|
$ 1.21 | -11.68 % | $ 55.3 M | Israel |
 |
AnaptysBio
ANAB
|
$ 48.4 | 0.9 % | $ 1.4 B | USA |
 |
Assembly Biosciences
ASMB
|
$ 21.33 | -2.11 % | $ 239 M | USA |
 |
Adagene
ADAG
|
$ 2.02 | -4.95 % | $ 119 M |  China |